3 results
The objective of this clinical investigation is to assess and characterize the clinical management of HeartMate 3 LVAD patients guided by hemodynamic parameters provided by the CardioMEMS HF System as a clinical hybrid construction to optimize…
Primary: to assess the effect of intravenous (IV) ozanezumab (15 mg/kg once every 2 weeks) compared to placebo on the physical function and survival of ALS patients over a treatment period of 48-weeks.Secondary (major): other clinical outcomes,…
We hypothesize that the CardioMEMS HF system will be safe and superior to standard care in improving the quality of life and health status in patients with chronic HF in the Netherlands. Additionally, we hypothesize the CardioMEMS HF system is cost-…